Amylyx's avexitide cut Level 2 and 3 hypoglycemic events by 55% in Phase 3. Why a GLP-1 receptor antagonist shows peptide therapeutics reach far past obesity drugs.
On 18 August 2026, Amylyx Pharmaceuticals reported that its Phase 3 LUCIDITY trial had met its primary endpoint. Avexitide, dosed once daily as a subcutaneous injection, reduced the composite rate of Level 2 and Level 3 hypoglycemic events by 55% against placebo, at a p-value of 0.000003 (Amylyx topline release).
The molecule behind that number is a peptide, and it binds the GLP-1 receptor — the target semaglutide and tirzepatide have turned into one of the most commercially consequential in medicine. Avexitide does the opposite thing to it.
How to read this article. Every factual claim below is linked to a company disclosure, trial document or clinical source. Sections headed Analysis are interpretation, not established fact. Avexitide is an investigational drug: it is not approved by the FDA or any other regulator.
Avexitide is a 31-amino-acid peptide, known in earlier literature as exendin(9-39) (Eiger BioPharmaceuticals). It is a fragment of exendin-4, the peptide isolated from the saliva of the Gila monster that gave rise to the diabetes drug exenatide.
Removing the first eight residues from the N-terminus leaves a molecule that still occupies the GLP-1 receptor but can no longer switch it on. What remains is a competitive antagonist: it sits in the binding site and blocks the native hormone.
Amylyx acquired the asset in July 2024 for $35.1 million plus cure costs and assumed liabilities, out of the bankruptcy of Eiger BioPharmaceuticals (acquisition announcement). The purchase followed the collapse of the company's ALS therapy Relyvrio, pulled from the market in April 2024 after the Phase 3 PHOENIX trial missed its endpoints (Fierce Pharma). LUCIDITY is the first pivotal win of the pipeline Amylyx rebuilt afterwards.
GLP-1 receptor agonists such as semaglutide and tirzepatide — the latter also engaging the GIP receptor — mimic the incretin hormone GLP-1. They activate the receptor, amplifying glucose-dependent insulin secretion, slowing gastric emptying and reducing appetite.
Avexitide occupies the same receptor and produces none of that signalling. In post-bariatric hypoglycemia the problem is not too little GLP-1 activity but far too much, so the therapeutic goal is to turn the volume down rather than up.
LUCIDITY offers a clean demonstration that the pharmacology behaves as described: across 16 weeks of double-blind treatment, neither the avexitide arm nor the placebo arm showed any change in body weight. A drug aimed at the receptor underpinning the obesity market produced no weight effect at all, which is exactly what blocking rather than activating it should do.
Post-bariatric hypoglycemia (PBH) is a rare, chronic metabolic condition that can emerge one to three years or more after bariatric surgery. Rerouted gut anatomy drives an exaggerated GLP-1 response to food, which triggers excessive insulin release and sends blood glucose sharply downward after meals (Amylyx disease overview).
Amylyx estimates PBH affects roughly 8% of people in the United States who have had a sleeve gastrectomy or Roux-en-Y gastric bypass — on the order of 160,000 people — and cites research in which more than 90% of patients report living with disability as a result.
Severity follows the standard classification used in diabetes care (ADA Standards of Care):
| Level | Definition |
|---|---|
| Level 1 | Glucose below 70 mg/dL and at or above 54 mg/dL |
| Level 2 | Glucose below 54 mg/dL, the threshold at which neuroglycopenic symptoms begin |
| Level 3 | A severe event with altered mental or physical status requiring another person's assistance, irrespective of the glucose reading |
Marilyn Tan of Stanford University, the trial's principal investigator, described these events as potential medical emergencies capable of causing cognitive impairment, loss of consciousness and seizures (Healio). There are currently no FDA-approved therapies for the condition.
LUCIDITY was a multicentre, randomised, double-blind, placebo-controlled trial run at approximately 20 US sites. Seventy-eight adults with PBH following Roux-en-Y gastric bypass were randomised 3:2 to 90mg of avexitide subcutaneously once daily or placebo, after a three-week run-in, across 16 weeks of blinded treatment with a 32-week open-label extension available afterwards (trial design).
The primary endpoint had been agreed with the FDA in advance. Beyond the 55% composite reduction, Amylyx reported that all secondary endpoints were met:
The company characterised the drug as generally well tolerated, with most adverse events mild to moderate, no serious adverse events attributed to avexitide, and diarrhoea plus injection-site redness and bruising the most common complaints.
Two limits are worth stating plainly. This is a topline company disclosure, not a peer-reviewed publication, and effect sizes for the individual secondary endpoints have not been released. Seventy-eight participants is also a small trial by the standards of metabolic medicine, though appropriate for a rare disease.
The most persuasive feature is replication. In the earlier Phase 2b study, the same 90mg daily dose produced a 53% reduction in Level 2 events and a 66% reduction in Level 3 events in just 16 participants. An independent Phase 3 cohort landing at a 55% composite reduction is the outcome you would predict if the Phase 2 signal was real rather than the artefact of a very small sample.
A p-value of 0.000003 in 78 people implies an effect large relative to its variance — the statistical result is not marginal. That is a comment on the strength of the observed difference, not a prediction of regulatory success, which turns on the complete dataset, manufacturing and labelling questions that topline figures cannot address.
Amylyx has said it intends to submit a New Drug Application to the FDA by the end of 2026, with a commercial launch anticipated in 2027 if the application succeeds. Avexitide holds Breakthrough Therapy Designation for both PBH and congenital hyperinsulinism, Orphan Drug Designation for hyperinsulinemic hypoglycemia, and Rare Pediatric Disease Designation in congenital hyperinsulinism. An expanded access programme opened in May 2026.
None of this constitutes approval. Breakthrough designation accelerates review and increases FDA engagement; it does not presuppose the outcome.
The public narrative around GLP-1 has been almost entirely an agonist narrative — a story about appetite and weight. Avexitide is a reminder that a receptor is a two-way switch, and that the clinically interesting direction is set by the disease rather than the market.
Three features of peptides make this kind of programme tractable:
The economics differ too. A 78-patient pivotal trial in a population of roughly 160,000 is a rare-disease programme, not a blockbuster one. If it succeeds, it demonstrates that peptide therapeutics can be aimed at small, well-defined populations where the biology is understood — a different proposition entirely from the obesity market that has dominated attention.
The caveat belongs in the same breath: this is one trial, in one indication, with an unresolved regulatory outcome.
No. Avexitide is investigational. Amylyx has stated it plans to file a New Drug Application by the end of 2026, and no regulator has approved the drug.
Semaglutide and tirzepatide are GLP-1 receptor agonists that activate the receptor. Avexitide is a competitive antagonist that blocks it. They act on the same target in opposite directions and are intended for entirely different conditions.
Amylyx reported no change in body weight in either the treatment or the placebo arm over the 16-week double-blind period.
Level 2 is defined by a glucose measurement below 54 mg/dL. Level 3 is defined by severity rather than a number: an event causing altered mental or physical status that requires another person's help to treat.
It is a truncated fragment of exendin-4, a peptide found in Gila monster saliva, and was previously designated exendin(9-39). Amylyx acquired it from Eiger BioPharmaceuticals in July 2024.
Disclaimer: This article is journalism about a clinical trial and is provided for educational purposes only. It is not medical advice, and it does not provide dosing, route or administration guidance. Avexitide is investigational and is not approved for use by any regulator. All products sold by us are supplied strictly for in-vitro laboratory and research use, not for human consumption.
Learn the correct technique for reconstituting lyophilised research peptides using bacteriostatic water for accurate, contamination-free preparations.
Research GuidesProper storage is critical to maintaining peptide integrity. Learn the correct temperature requirements and handling practices for lyophilised and reconstituted peptides.
99%+ HPLC purity · COA verified every batch · Next-day dispatch to Melbourne
Shop All Peptides